Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Could octreotide become a first‑line systemic option in VWD patients with angiodysplasia‑related GI bleeding?
Great talk by Sophie Susen at the EHA meeting in Florence on angiodysplasia‑related GI bleeding and the implications of the OCEAN trial for VWD.
OCEAN trial:
- Multicenter RCT in 62 patients with transfusion‑dependent angiodysplasia‑related anemia, Octreotide LAR 40 mg q4w vs standard care.
- About 50% reduction in transfusion requirements (11.0 vs 21.2 units), alongside fewer endoscopic procedures and hospitalizations, with a generally favourable safety profile.
What octreotide actually does
Octreotide, a long‑acting somatostatin analogue, reduces splanchnic blood flow and portal pressure, improves platelet aggregation, and exerts anti‑angiogenic effects via inhibition of VEGF and other growth factors.
This mechanistic profile makes it particularly attractive for chronic bleeding from GI angiodysplasia.
What this could mean for VWD
Even though VWD patients were not included in OCEAN, these robust data provide the best evidence we currently have for systemic therapy in angiodysplasia‑related bleeding and strongly support octreotide as a potential first‑line systemic option in this setting.
Case reports and small series in VWD already suggest benefit, but dedicated prospective trials in VWD with angiodysplasia are urgently needed to define efficacy, safety, and optimal positioning in future treatment algorithms.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?